Harmony Biosciences (HRMY) Q4 2024 earnings summary

Executive summary

• Achieved record net product revenue of $714.7 million for FY 2024 (up 23% YoY) and $201.3 million for Q4 2024, driven by strong WAKIX sales and expanding patient base.

• Advanced a robust late-stage CNS pipeline, with multiple Phase 3 trials and regulatory milestones anticipated in 2025 and beyond.

• Announced first generic settlement agreement for pitolisant, reinforcing IP strength and extending exclusivity to 2030 or later.

• Ended 2024 with $576.1 million in cash, cash equivalents, and investments, supporting pipeline expansion and value creation.

• Positioned for a transformational 2025 with multiple late-stage clinical milestones and a strong balance sheet.

Financial highlights

• FY 2024 net revenue reached $714.7 million, a 23% increase from 2023; Q4 2024 net revenue was $201.3 million, up 20% YoY.

• Q4 2024 GAAP net income was $49.5 million ($0.85/diluted share); non-GAAP adjusted net income was $63 million ($1.08/diluted share).

• FY 2024 GAAP net income was $145.5 million ($2.51/diluted share); non-GAAP adjusted net income was $233.9 million ($4.04/diluted share).

• Operating expenses for FY 2024 were $367.1 million, up 37% YoY, mainly due to R&D and licensing fees.

• Cash, cash equivalents, and investments totaled $576.1 million at year-end 2024.

Outlook and guidance

• 2025 net revenue guidance set at $820–$860 million, reflecting continued strong growth expectations.

• Multiple late-stage clinical readouts expected, including ZYN-002 in Fragile X syndrome (Q3 2025) and Pitolisant HD trials initiation (Q4 2025).

• Pipeline has potential to deliver over $3 billion in net revenue in coming years with at least one new product/indication launch annually.

• Anticipates typical seasonal revenue dynamics, with Q1 headwinds and Q2/Q4 tailwinds.

• Plans for increased R&D investments and up to $29 million in milestone payments in 2025.